[go: up one dir, main page]

EP1656128A1 - Traitement de l'acne simple et procede d'utilisation - Google Patents

Traitement de l'acne simple et procede d'utilisation

Info

Publication number
EP1656128A1
EP1656128A1 EP03818329A EP03818329A EP1656128A1 EP 1656128 A1 EP1656128 A1 EP 1656128A1 EP 03818329 A EP03818329 A EP 03818329A EP 03818329 A EP03818329 A EP 03818329A EP 1656128 A1 EP1656128 A1 EP 1656128A1
Authority
EP
European Patent Office
Prior art keywords
treatment
acne vulgaris
ethoxylate
composition
exchanged
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03818329A
Other languages
German (de)
English (en)
Other versions
EP1656128A4 (fr
Inventor
William M. Yarbrough
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
William M Yarbrough Foundation
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP1656128A1 publication Critical patent/EP1656128A1/fr
Publication of EP1656128A4 publication Critical patent/EP1656128A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/39—Derivatives containing from 2 to 10 oxyalkylene groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
    • A61K8/86—Polyethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Definitions

  • the present invention relates to a composition including surfactants for the treatment of acne vulgaris. Methods of use are also included ⁇ . BACKGROUND OF THE INVENTION AND PRIOR ART Acne vulgaris (or "acne") is a disorder of the sebaceous glands. It is characterized by lesions that are either non-inflammatory or inflammatory papules and nodules. Non-inflammatory papules may be open, commonly referred to as “blackheads", or closed, commonly referred to as “whiteheads”. As a group, non- inflammatory papules are called comedones.
  • a topical treatment for acne 5 vulgaris a topical treatment for acne 5 vulgaris.
  • a method is provided for applying a composition of 6 substances to the infected area, working the composition into the infected area, and 7 removing the composition from the infected area.
  • the composition comprises at least 8 one ethoxylate in combination with Sodium Lauroyl Sarcosinate (or "SLS").
  • SLS Sodium Lauroyl Sarcosinate
  • An inert 9 scrubbing agent such as polyethylene beads, can also be included to the formula.
  • Acetylated lanolin alcohol, a second ethoxylate, EDTA, a foam stabilizer, and water can 11 also be added to the composition without effecting performance.
  • Other formulas that keep the polarity similar to that of the inventive formula will 13 also work. To keep the polarity similar, it is necessary for the compound to have similar 14 characteristics, such as Carbon chains, carbonyl groups, Nitrogen bound to Carbon, 15 Aromatic ring(s), Oxylate groups, and appropriate functional groups at the ends of the 16 individual molecules.
  • the ideal substitute chemicals would have all of the characteristics 17 mentioned above, but it is not necessary to have every one of those as listed.
  • the cutting agent must be added only in 2 sufficient amount that it promotes flow but does not effect the action of the composition. 3
  • an sufficient amount of the composition is used to cover the infected area, 4 the composition is applied to an infected area and worked over the area by a scrubbing 5 motion. After sufficient time has elapsed to ensure that the infected area has been 6 adequately exposed to the composition such that they area feels clean, approximately ten 7 to thirty seconds for the typical person, the area is rinsed cleaned.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne un traitement de l'acné simple, aux fins de traitement topique. On décrit un procédé d'application de substances à base de composition sur la zone visée, laissant ensuite la composition pénétrer, et éliminant enfin la composition. Ladite composition comprend au moins un éthoxylate combiné à du sarcosinate de lauroyle sodique. Selon une variante, l'éthoxylate peut être remplacé par un méthoxylate ou un propoxylate. On peut aussi incorporer un agent de pelage inerte, du type billes de polyéthylène. On peut enfin contribuer à la performance en incorporant les produits suivants : alcool de lanoline acétylé, sarcosinate de lauroyle sodique, EDTA, stabilisant de mousse, et eau.
EP03818329A 2003-08-12 2003-08-12 Traitement de l'acne simple et procede d'utilisation Withdrawn EP1656128A4 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2003/025207 WO2005018629A1 (fr) 2003-08-12 2003-08-12 Traitement de l'acne simple et procede d'utilisation

Publications (2)

Publication Number Publication Date
EP1656128A1 true EP1656128A1 (fr) 2006-05-17
EP1656128A4 EP1656128A4 (fr) 2007-02-28

Family

ID=34215304

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03818329A Withdrawn EP1656128A4 (fr) 2003-08-12 2003-08-12 Traitement de l'acne simple et procede d'utilisation

Country Status (5)

Country Link
EP (1) EP1656128A4 (fr)
JP (1) JP2007521234A (fr)
AU (1) AU2003264053A1 (fr)
CA (1) CA2535550A1 (fr)
WO (1) WO2005018629A1 (fr)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2115004A2 (fr) 2006-12-19 2009-11-11 Ablynx N.V. Sequences d'acides amines dirigees contre les gpcr et polypeptides les contenant pour le traitement de maladies et de troubles lies au gpcr
US9512236B2 (en) 2006-12-19 2016-12-06 Ablynx N.V. Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
US9156914B2 (en) 2006-12-19 2015-10-13 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
FR2923383B1 (fr) * 2007-11-08 2010-03-19 Oreal Utilisation d'un sarcosinate n-acyle comme agent anti-adhesion microbienne.
EP2215125A1 (fr) 2007-11-27 2010-08-11 Ablynx N.V. Procédé d'obtention de produits de construction de polypeptide comprenant au moins deux anticorps à domaine unique
CA2717015A1 (fr) 2008-03-05 2009-09-11 Ablynx Nv Nouveaux complexes dimeres de fixation a des antigenes, procedes de fabrication et utilisations associes
JP2011516520A (ja) 2008-04-07 2011-05-26 アブリンクス エン．ヴェー． Ｎｏｔｃｈ経路に指向性を有するアミノ酸配列及びその使用
RU2010151725A (ru) 2008-05-16 2012-06-27 Аблинкс Нв (Be) Аминокислотные последовательности, направленные против cхcr4 и других gpcr, и соединения, включаюшие их
HUE042053T2 (hu) 2008-06-05 2019-06-28 Ablynx Nv Vírus burokfehérjéi elleni aminosav-szekvenciák és az azokat tartalmazó polipeptidek virális betegségek kezelésére
EP2352764B1 (fr) 2008-10-14 2018-03-28 Ablynx N.V. Séquences des acides aminés ciblant cd4 et cxcr4, ccr5, tlr4, alphav integrin, beta3-integrin, beta1-integrin, alpha2-integrin humain, cd81, sr-bi, claudin-1, claudin-6 et/ou claudin-9 humain, respectivement, et neutralisant l'entrée virale
US8858940B2 (en) 2008-12-10 2014-10-14 Ablynx N.V. Amino acid sequences directed against the Angiopoietin/Tie system and polypeptides comprising the same for the treatment of diseases and disorders related to angiogenesis
WO2010100135A1 (fr) 2009-03-05 2010-09-10 Ablynx N.V. Nouveaux complexes dimères de liaison antigénique, méthodes d'obtention/non obtention et leurs utilisations
BRPI1013877A2 (pt) 2009-04-10 2017-08-15 Ablynx Nv Sequências de aminoácidos melhoradas contra il-6r e polipeptídeos que compreendem os mesmos para o tratamento de doenças e distúrbios relacionados com il-6r
DK2424889T3 (en) 2009-04-30 2015-11-02 Ablynx Nv Process for the preparation of domain antibodies
PL2438087T3 (pl) 2009-06-05 2017-10-31 Ablynx Nv Triwalentne konstrukty nanociał przeciwko ludzkiemu syncytialnemu wirusowi oddechowemu (hRSV) do zapobiegania i/lub leczenia zakażeń dróg oddechowych
EP2451839B1 (fr) 2009-07-10 2020-04-22 Ablynx N.V. Procédé pour la production de domaines variables
SI2805731T1 (sl) 2009-09-03 2019-02-28 Ablynx N.V. Stabilne formulacije polipeptidov in njihove uporabe
US9644022B2 (en) 2009-11-30 2017-05-09 Ablynx N.V. Amino acid sequences directed against human respiratory syncytial virus (HRSV) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
EP3309176A1 (fr) 2009-12-14 2018-04-18 Ablynx N.V. Immunoglobulin anticorps à domaine variable unique contre ox40l, constructions et utilisation thérapeutique
WO2011083141A2 (fr) 2010-01-08 2011-07-14 Ablynx Nv Procédé de production de séquences d'immunoglobulines par utilisation de particules de lipoprotéines
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
SI2533761T1 (sl) 2010-02-11 2019-08-30 Ablynx N.V. Postopki in sestavki za pripravo aerosolov
EP2552962B1 (fr) 2010-03-26 2016-03-23 Ablynx N.V. Domaines variables uniques d'immunoglobulines dirigés contre cxcr7
RU2012149227A (ru) 2010-05-20 2014-06-27 Аблинкс Нв Биологические материалы, относящиеся к her3
WO2011161263A1 (fr) 2010-06-25 2011-12-29 Ablynx Nv Compositions pharmaceutiques destinées à une administration par voie cutanée
PL3279214T3 (pl) 2010-10-29 2025-03-24 Ablynx Nv Sposób wytwarzania pojedynczych domen zmiennych immunoglobuliny
CN108341868B (zh) 2010-11-05 2022-06-07 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
BR112013011003B1 (pt) 2010-11-08 2021-12-07 Novartis Ag Polipeptídeo e seus usos, célula hospedeira transgênica de microrganismo, nanocorpo monovalente, bivalente, multivalente, biparatópico ou multiparatópico, e composição farmacêutica
ES2688591T3 (es) 2011-03-28 2018-11-05 Ablynx N.V. Método para producir formulaciones sólidas que comprenden dominios variables individuales de inmunoglobulina
CN103917560B (zh) 2011-03-28 2017-05-24 埃博灵克斯股份有限公司 双特异性抗‑cxcr7免疫球蛋白单可变结构域
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
EP2707382B1 (fr) 2011-05-09 2019-07-17 Ablynx NV Procédé pour la production de domaines variables uniques d'immunoglobuline
AU2012264809B2 (en) 2011-05-27 2017-05-04 Ablynx Nv Inhibition of bone resorption with RANKL binding peptides
IN2014CN00437A (fr) 2011-06-23 2015-04-03 Ablynx Nv
US10138302B2 (en) 2011-09-23 2018-11-27 Ablynx N.V. Methods for treating rheumatoid arthritis by administering interleukin-6 receptor antibodies
CN109897103B (zh) 2011-11-04 2024-05-17 酵活英属哥伦比亚有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
ES2843054T3 (es) 2012-05-10 2021-07-15 Zymeworks Inc Construcciones heteromultiméricas de cadenas pesadas de inmunoglobulina con mutaciones en el dominio Fc
US9499634B2 (en) 2012-06-25 2016-11-22 Zymeworks Inc. Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
US9914785B2 (en) 2012-11-28 2018-03-13 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
WO2014183066A2 (fr) 2013-05-10 2014-11-13 Whitehead Institute For Biomedical Research Modification protéique de cellules vivantes à l'aide de sortase
EP2883883A1 (fr) 2013-12-16 2015-06-17 Cardio3 Biosciences S.A. Cibles thérapeutiques et agents utiles dans le traitement des lésions ischémiques de reperfusion
NL2013007B1 (en) 2014-06-16 2016-07-05 Ablynx Nv Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
SG11201702699TA (en) 2014-10-10 2017-04-27 Ablynx Nv Inhalation device for use in aerosol therapy of respiratory diseases
CN107206069A (zh) 2014-10-10 2017-09-26 埃博灵克斯股份有限公司 Rsv感染的治疗
JP6862343B2 (ja) 2014-12-19 2021-04-21 アブリンクス エン．ヴェー． システイン結合ナノボディダイマー
TN2018000180A1 (en) 2015-11-27 2019-10-04 Ablynx Nv Polypeptides inhibiting cd40l
SE543153C2 (en) 2016-05-19 2020-10-13 Biocool Ab Aqueous hydrogen peroxide solution obtained from a dry composition comprising sodium percarbonate for skin treatment
CA3026108A1 (fr) 2016-06-10 2017-12-14 Clarity Cosmetics Inc. Formulations non comedogenes de soin des cheveux et du cuir chevelu et methode d'utilisation
WO2018007442A1 (fr) 2016-07-06 2018-01-11 Ablynx N.V. Traitement de maladies associées à l'il-6r
WO2018029182A1 (fr) 2016-08-08 2018-02-15 Ablynx N.V. Anticorps à domaine variable unique d'il-6r pour le traitement de maladies liées à l'il-6r
EP3512880A1 (fr) 2016-09-15 2019-07-24 Ablynx NV Domaines variables uniques d'immunoglobuline dirigés contre le facteur inhibiteur de la migration des macrophages
IL317416A (en) 2016-11-16 2025-02-01 Ablynx Nv T cell-recruiting polypeptides capable of binding CD123 and TCR alpha/beta
WO2018099968A1 (fr) 2016-11-29 2018-06-07 Ablynx N.V. Traitement d'une infection par le virus respiratoire syncytial (vrs)
CA3054623A1 (fr) 2017-02-28 2018-09-07 Vib Vzw Moyens et procedes d'administration de proteines par voie orale
EP3621990A1 (fr) 2017-05-11 2020-03-18 VIB vzw Glycosylation de domaines variables d'immunoglobuline
CN110997716B (zh) 2017-06-02 2024-03-15 埃博灵克斯股份有限公司 结合聚集蛋白聚糖的免疫球蛋白
HRP20241562T1 (hr) 2017-06-02 2025-01-31 Merck Patent Gmbh Adamts vezujući imunoglobulini
US12129308B2 (en) 2017-06-02 2024-10-29 Merck Patent Gmbh MMP13 binding immunoglobulins
KR102740376B1 (ko) 2017-06-02 2024-12-09 메르크 파텐트 게엠베하 Adamts5, mmp13 및 아그레칸 결합성 폴리펩타이드
WO2019016237A1 (fr) 2017-07-19 2019-01-24 Vib Vzw Agents de liaison à la l'albumine sérique
EP3704160A1 (fr) 2017-10-31 2020-09-09 VIB vzw Nouvelles protéines chimériques de liaison à l'antigène, procédés et utilisations de celles-ci
IL276200B2 (en) 2018-02-06 2025-01-01 Ablynx Nv Polypeptide comprising two variable domains of anti-human (vWF) immunoglobulins VON- for use in the treatment of a first episode of von Willebrand Factor (vWF)-related disease
CA3092421A1 (fr) 2018-03-01 2019-09-06 Vrije Universiteit Brussel Immunoglobulines se liant au pd-l1 humain
PL3768701T3 (pl) 2018-03-23 2024-02-19 Université Libre de Bruxelles Cząsteczki agonistów sygnalizacji WNT
EP4378485A3 (fr) 2019-03-08 2024-08-28 LinXis B.V. Internalisation de molécules de liaison ciblant des récepteurs impliqués dans la prolifération cellulaire ou la différenciation cellulaire
EP3976650A1 (fr) 2019-05-28 2022-04-06 Vib Vzw Traitement du cancer par ciblage des plexines dans le compartiment immunitaire
US20220228116A1 (en) 2019-05-28 2022-07-21 Vib Vzw Cd8+ t-cells lacking plexins and their application in cancer treatment
GB201918279D0 (en) 2019-12-12 2020-01-29 Vib Vzw Glycosylated single chain immunoglobulin domains
US20230279115A1 (en) 2020-04-22 2023-09-07 Mabwell (shanghai) Bioscience Co., Ltd. Single variable domain antibody targeting human programmed death ligand 1 (pd-l1) and derivative thereof
WO2021229104A1 (fr) 2020-05-15 2021-11-18 Université de Liège Anticorps anti-cd38 à domaine unique pour la surveillance et le traitement de maladies
EP4214235A1 (fr) 2020-09-16 2023-07-26 LinXis B.V. Internalisation de molécules de liaison
WO2022063957A1 (fr) 2020-09-24 2022-03-31 Vib Vzw Biomarqueur pour une thérapie antitumorale
CA3196737A1 (fr) 2020-09-24 2022-03-31 Massimiliano Mazzone Combinaison d'inhibiteurs de p2y6 et d'inhibiteurs de points de controle immunitaire
PH12023500013A1 (en) 2020-12-04 2024-03-11 Tidal Therapeutics Inc Ionizable cationic lipids and lipi nanoparticles, and methods of synthesis and use thereof
CN117241804A (zh) 2021-02-17 2023-12-15 非营利性组织佛兰芒综合大学生物技术研究所 在癌症治疗中slc4a4的抑制
IL305301A (en) 2021-02-19 2023-10-01 Us Health SINGLE DOMAIN ANTIBODIES THAT NEUTRALIZE SARS-CoV-2
US20240261446A1 (en) 2021-05-17 2024-08-08 Université de Liège Anti-cd38 single domain antibodies in disease monitoring and treatment
EP4367130A1 (fr) 2021-07-09 2024-05-15 Luxembourg Institute of Health (LIH) Complexes protéiques dimères et leurs utilisations
AR129560A1 (es) 2022-06-08 2024-09-04 Tidal Therapeutics Inc Lípidos catiónicos ionizables y nanopartículas lipídicas, y métodos de síntesis y uso de los mismos
WO2024008755A1 (fr) 2022-07-04 2024-01-11 Vib Vzw Anticorps de traversée de barrière de fluide céphalorachidien
WO2024008274A1 (fr) 2022-07-04 2024-01-11 Universiteit Antwerpen Modification de lymphocytes t régulateurs
WO2024083843A1 (fr) 2022-10-18 2024-04-25 Confo Therapeutics N.V. Séquences d'acides aminés dirigées contre le récepteur de la mélanocortine 4 et polypeptides les comprenant pour le traitement de maladies et de troubles liés à mc4r
AR131441A1 (es) 2022-12-21 2025-03-19 Genzyme Corp Proteínas de unión anti-pd-1 ´ 4-1bb
WO2024156881A1 (fr) 2023-01-27 2024-08-02 Vib Vzw Polypeptides de liaison à cd8b
WO2024156888A1 (fr) 2023-01-27 2024-08-02 Vib Vzw Conjugués de liaison à cd163
WO2024208816A1 (fr) 2023-04-03 2024-10-10 Vib Vzw Anticorps traversant la barrière hémato-encéphalique
WO2024231348A1 (fr) 2023-05-11 2024-11-14 Vib Vzw Inhibiteurs de slc4a4/nbce1
WO2024251783A1 (fr) 2023-06-05 2024-12-12 Sanofi Prédiction de stabilités thermiques de domaines variables uniques d'immunoglobuline à l'aide de modèles d'apprentissage automatique
EP4483951A1 (fr) 2023-06-30 2025-01-01 Université de Liège Anticorps à domaine unique pour l'inhibition de l'activité de l'élastase neutrophile
US12138428B1 (en) 2024-01-24 2024-11-12 Sanofi Electronic add-on module and assembly of an electronic add-on module and a drug delivery device
US12144969B1 (en) 2024-02-28 2024-11-19 Sanofi Attachment mechanism, module and assembly herewith
US12239828B1 (en) 2024-03-28 2025-03-04 Sanofi Attachment mechanism, module and assembly herewith
US12186538B1 (en) 2024-05-10 2025-01-07 Sanofi Electronic add-on module and assembly of an electronic add-on module and a drug delivery device
US12213944B1 (en) 2024-05-16 2025-02-04 Genzyme Corporation Fluid transfer device
US12171719B1 (en) 2024-05-16 2024-12-24 Genzyme Corporation Fluid transfer device
US12226371B1 (en) 2024-05-16 2025-02-18 Genzyme Corporation Fluid transfer device

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4147782A (en) * 1976-06-24 1979-04-03 William H. Rorer, Inc. Pharmaceutical detergent composition
WO2000003686A2 (fr) * 1998-07-20 2000-01-27 Sarlo Peter V Compositions pour traiter l'acne
US6423746B1 (en) * 1999-07-03 2002-07-23 The William M. Yarbrough Foundation Urushiol induced contact dermatitis and method of use
US20020183284A1 (en) * 1999-07-03 2002-12-05 Yarbrough William M. Urushiol induced contact dermatitis solution

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1539031A (en) * 1975-02-22 1979-01-24 Beecham Group Ltd Pharmaceutical compositions

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4147782A (en) * 1976-06-24 1979-04-03 William H. Rorer, Inc. Pharmaceutical detergent composition
WO2000003686A2 (fr) * 1998-07-20 2000-01-27 Sarlo Peter V Compositions pour traiter l'acne
US6423746B1 (en) * 1999-07-03 2002-07-23 The William M. Yarbrough Foundation Urushiol induced contact dermatitis and method of use
US20020183284A1 (en) * 1999-07-03 2002-12-05 Yarbrough William M. Urushiol induced contact dermatitis solution

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2005018629A1 *

Also Published As

Publication number Publication date
JP2007521234A (ja) 2007-08-02
WO2005018629A1 (fr) 2005-03-03
CA2535550A1 (fr) 2005-03-03
AU2003264053A1 (en) 2005-03-10
EP1656128A4 (fr) 2007-02-28

Similar Documents

Publication Publication Date Title
WO2005018629A1 (fr) Traitement de l'acne simple et procede d'utilisation
US6423746B1 (en) Urushiol induced contact dermatitis and method of use
US4395398A (en) Dental hemostatic composition
US9730870B2 (en) Sodium hypochlorite-based body wash compositions
JP3434435B2 (ja) ふけ形成抑制効果を有する毛髪化粧料組成物
CN108066164B (zh) 一种透明的复合型清洁组合物及其制备方法
EP1882480A2 (fr) Agents de nettoyage antimicrobiens à haute teneur en glycérine
NZ555336A (en) Topical pharmaceutical compositions containing an antiacne compound and antibiotic compound
JP2008533037A (ja) 過酸化ベンゾイル組成物およびその使用方法
EP1933840B1 (fr) Utilisation de delmopinol pour le traitement de l'acne
US7008963B2 (en) Urushiol induced contact dermatitis solution
JP2001504153A (ja) 殺菌性ソープバー
WO2002002104A1 (fr) Traitement de la dermatite de contact provoquee par urushiol et procede correspondant
JP2668853B2 (ja) 台所用洗剤
EP1189584A1 (fr) Soin et composition dermatologique a base d'acide alpha-amine
CN111743793A (zh) 一种洗手液及其制备方法
JPH0559889B2 (fr)
JPH0324443B2 (fr)
JP3293692B2 (ja) ヨード配合砂場用殺菌剤組成物
WO2004052358A1 (fr) Traitement topique des dermatites dues a un contacts avec de l'urushiol, et methodes d'utilisation associees
CA1220426A (fr) Methode de traitement de l'acne et compose contenant du peroxyde de carbamide
JP2007502289A (ja) 刺咬性及び侵入性生物並びに寄生生物と蕁麻疹の治療用組成物、並びに使用方法
EP1982694B1 (fr) Composition anti-'dème
US20050037039A1 (en) Composition for treatment of tinea pedis and method of use
JP2005527601A (ja) 二糖類及び金属イオンによる、刺激の阻止のための方法及び組成物

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060310

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

A4 Supplementary search report drawn up and despatched

Effective date: 20070126

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/085 20060101AFI20070122BHEP

Ipc: A61P 17/10 20060101ALI20070122BHEP

Ipc: A61K 31/198 20060101ALI20070122BHEP

Ipc: A61K 45/06 20060101ALI20070122BHEP

17Q First examination report despatched

Effective date: 20070404

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: THE WILLIAM M. YARBROUGH FOUNDATION

RIN1 Information on inventor provided before grant (corrected)

Inventor name: WILLIAM M. YARBROUGH

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070817